Form 4: BioMarin EVP Granted RSUs, Options; Sells Shares for Tax

BioMarin Pharmaceutical's EVP, Chief R&D Officer, Gregory R. Friberg, reported the grant of restricted stock units and stock options, alongside a sale of common stock for tax withholding purposes.

Summary

• Gregory R. Friberg, EVP, Chief R&D Officer at BioMarin Pharmaceutical Inc. (BMRN), reported transactions involving the company's common stock and derivative securities.
• On March 16, 2026, Friberg was granted 19,150 restricted stock units (RSUs) of common stock at a price of $0, increasing his direct beneficial ownership to 56,728 shares.
• Also on March 16, 2026, Friberg was granted 45,600 stock options to buy common stock with an exercise price of $57.43.
• These stock options begin vesting 12/48th on March 16, 2027, and 1/48th on the 16th day of each month thereafter, with an expiration date of March 15, 2036.
• On March 17, 2026, Friberg disposed of 1,629 shares of common stock at a price of $56.05 per share, reducing his direct beneficial ownership to 55,099 shares. This disposition is typically for tax withholding related to RSU vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction report reflecting standard executive compensation. The grants of RSUs and options are mildly positive for aligning management incentives, while the tax-related sale is a common occurrence.

Positives

• The grant of 19,150 restricted stock units (RSUs) aligns management's interests with shareholders.
• The grant of 45,600 stock options provides an incentive for long-term performance and value creation.

Negatives

• The disposition of 1,629 shares of common stock, even for tax purposes, represents a reduction in direct ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted stock options.

Industry Context

StockSavvy.ai notes that executive compensation packages, including restricted stock units and stock options, are standard practice in the biotechnology and pharmaceutical industries. These grants are designed to align the interests of key executives, such as Chief R&D Officers, with long-term shareholder value creation, incentivizing innovation and successful product development.

Stakeholder Impact

• Shareholders: The grants align executive incentives with shareholder value, potentially leading to better long-term performance. The small sale for tax purposes has negligible impact.

Next Steps

• The granted stock options will begin vesting on March 16, 2027, with subsequent monthly vesting.

Key Dates

Keywords

BioMarin Pharmaceutical, BMRN, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Gregory R. Friberg, Biotechnology